Innovative Medical: 2025 Independent Director Work Report (Yao Hangping)
Innovative Medical Management Co., Ltd.
2025 Independent Directors’ Work Report
Dear shareholders and shareholder representatives:
As an independent director of Innovative Medical Management Co., Ltd. (hereinafter referred to as the "Company"), in accordance with the requirements of the "Company Law", "Securities Law", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operations of Main Board Listed Companies", "Administrative Measures for Independent Directors of Listed Companies" and the company's Articles of Association, in 2025 During the year, he diligently performed his duties, independently, prudently and seriously exercised the rights granted by the company, kept abreast of the company's operating conditions, actively attended relevant meetings held by the company, carefully reviewed various proposals, gave full play to the role of independent directors and members of various professional committees, and effectively safeguarded the legitimate rights and interests of the company and all shareholders, especially public shareholders. I would like to report my performance of duties in 2025 as follows:
1. Basic information of independent directors
(1) Basic situation
I am Yao Hangping, Chinese nationality, born in 1972, with a master’s degree. He works in the National Key Laboratory of Diagnosis and Treatment of Severe Infectious Diseases at the First Affiliated Hospital of Zhejiang University, and serves as an academic part-time member of the HIV Virology Professional Committee of the Chinese Association for the Prevention and Treatment of STDs and AIDS, the Vaccine Professional Committee of the China Medical Biotechnology Association, the Laboratory Medicine Professional Committee of the Chinese Society of Integrated Traditional Chinese and Western Medicine, the Tumor Immunity Experimental Diagnosis Expert Committee, the Infectious Diseases Professional Committee of the Zhejiang Mathematical Medicine Society, the Tropical and Parasitic Diseases Branch of the Zhejiang Medical Association, and the Zhejiang Society of Immunology. Mainly engaged in research on the diagnosis and treatment of infectious diseases and targeted biological therapy of malignant tumors. His research results have won 1 special prize of the National Science and Technology Progress Award, 1 first prize of the National Science and Technology Progress Award, 1 first prize of the Chinese Medical Science and Technology Award, 1 first prize of the Zhejiang Province Science and Technology Progress Award, and 8 second and third prizes. He will serve as an independent director of the company from March 2022.
(2) Description of independence
As an independent director of the company, after self-examination, I have found that I comply with the relevant requirements for the independence of independent directors in relevant laws and regulations such as the "Administrative Measures for Independent Directors of Listed Companies", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operation of Main Board Listed Companies", and there is no situation that affects independence.
1/5
2. Annual performance overview of independent directors
(1) Attending the company’s board of directors and attending the company’s shareholders’ meeting
The company will hold a total of 13 board meetings in 2025. My attendance is as follows:
Held during the reporting period Attendance on site Attendance via communication Attendance by proxy Type of absentee meeting
times times times times times board of directors 13 0 13 0 0
In 2025, I actively participated in the company's board of directors meetings, carefully reviewed the meeting proposals and related materials with a diligent and responsible attitude, actively participated in the discussion of various proposals, and put forward reasonable opinions based on my professional background and experience. At the same time, I actively paid attention to the implementation of the board of directors' resolutions by the company's management, and played an active role in the scientific and efficient decision-making of the board of directors. I voted in favor of all resolutions at the board of directors meetings during the reporting period, and did not object or abstain from voting.
The company held 3 shareholders' meetings in 2025, and I attended 0 times.
I believe that the convening and convening of the company's board of directors and shareholders' meeting are in compliance with legal procedures, major business decision-making matters and other major matters have implemented standardized approval procedures, and the resolutions safeguard the rights and interests of all shareholders, especially small and medium-sized shareholders.
(2) Attendance at special committees of the board of directors
In 2025, as a member of the company's sixth strategy committee and audit committee, chairman of the seventh nomination committee and remuneration and assessment committee, and member of the strategy committee and audit committee, I will actively participate in the daily work of the special committees in accordance with the requirements of the company's working rules of each special committee, conscientiously perform my duties, actively attend each meeting, and there will be no entrustment or absence of others. At the same time, as a medical professional, he analyzed the company's strategic plan based on the industry situation and the company's actual development; reviewed the company's annual financial report audit arrangements, supervised the progress of the audit work many times, inspected and reviewed the company's financial reports, paid attention to the implementation of the company's internal control system, and reviewed the company's annual financial final report and other proposals; reviewed the company's proposals for senior management personnel to be hired, strictly verified the qualifications of the proposed personnel, and conducted necessary supervision on the company's salary implementation. In the above aspects, we have effectively performed our duties as members of the special committee, actively reviewed relevant proposals and put forward reasonable suggestions to standardize the company's operations and improve the company's internal control. During the reporting period, my attendance at the special committees of the Board of Directors is as follows:
Session Category of special committees Number of meetings held during the reporting period Number of meetings attended by me Sixth session Strategy Committee 1 1
The Sixth Audit Committee 2 2
2/5
The Seventh Audit Committee 3 3
The 7th Nomination Committee 1 1
(3) Exercising the powers of independent directors
In 2025, I did not independently hire an intermediary agency to audit, consult or verify specific matters of the company, propose to the board of directors to convene an extraordinary shareholders' meeting, propose to convene a board of directors meeting, publicly solicit shareholders' rights from shareholders, etc., which must be reviewed by a special meeting of independent directors.
(4) Communication with internal audit institutions and accounting firms
In 2025, I will actively communicate with the company's internal audit institution and accounting firm, review the company's internal audit work summary and plan, have an in-depth understanding of the company's internal control construction, and review the annual audit plan submitted by the accountant in advance, fully communicate with them, communicate with them on key audit matters, audit points, audit staffing and other matters, pay attention to the audit process, supervise the audit progress, and ensure that the audit work is timely, accurate, objective, and fair.
(5) Communication with small and medium-sized shareholders and safeguarding the legitimate rights and interests of investors
In 2025, I will actively pay attention to the questions raised by the company's shareholders on Shenzhen Stock Exchange Interactive and other platforms to understand the thoughts and concerns of the company's shareholders; read company announcements in a timely manner and actively pay attention to the company's shareholders and the public's evaluation of the company; focus on participating in the company's investor management work, and effectively safeguard the legitimate interests of all shareholders, especially small and medium-sized shareholders.
(6) Working time and content on-site at the company, etc.
In 2025, I took advantage of the opportunity to participate in the board of directors and other times to conduct on-site inspections of the company, accumulating 15 days of on-site work time. Carefully listen to the company management's reports on the company's production and operation status, financial situation, subsidiary management and other aspects of the company's internal governance and standardized operations, and focus on inspecting the company's operation and management, internal control and other system construction and implementation, and the implementation of board resolutions; maintain close contact with other directors, senior managers and relevant staff of the company on a daily basis, always pay attention to the impact of external environment and market changes on the company, pay attention to relevant reports about the company in the media and the Internet, and be informed of the progress of the company's major events in a timely manner, and understand the company's operating dynamics.
(7) The company’s cooperation with independent directors
In 2025, the company carefully organized relevant meetings, delivered documents and materials in a timely manner and reported on the company's operating conditions, providing sufficient conditions for independent directors to perform their duties, and providing active support and cooperation. There was no situation that hindered independent directors from performing their duties.
3/5
3. Matters of focus in annual performance of duties
In 2025, I will strictly comply with laws and regulations such as the Company Law, the Code of Governance of Listed Companies, the Measures for the Administration of Independent Directors of Listed Companies, and the company's Articles of Association, perform my duties faithfully, give full play to the role of an independent director, and safeguard the legitimate rights and interests of the company and all shareholders, especially small and medium-sized shareholders. In 2025, the key matters to focus on are as follows:
(1) Disclosure of regular reports and internal control evaluation reports
In 2025, the company prepared and disclosed the "2024 Annual Report", "2025 First Quarter Report", "2025 Semi-Annual Report", and "2025 Third Quarter Report" on time, accurately disclosed the financial data and important matters during the corresponding reporting period, and fully presented the company's financial status, operating results and cash flow to investors. I have carefully reviewed the full text of the periodic report. The above reports were reviewed and approved by the company's board of directors. The company's directors and senior managers all signed written confirmation opinions on the company's periodic reports. The company's review and disclosure procedures for periodic reports are legal and compliant, and the financial data are detailed and truly reflect the company's actual situation.
In accordance with the enterprise's internal control standard system, the company organized and carried out internal control evaluation work on the basis of daily supervision of internal control and various special supervisions. On April 23, 2026, the second meeting of the seventh board of directors reviewed and approved the "2025 Internal Control Self-Evaluation Report". I believe that the company's internal control is effective, and the company's self-evaluation report on internal control truly and objectively reflects the current actual situation of the company's internal control system construction, implementation and supervision.
(2) Employment of accounting firms
The company held the seventh meeting of the sixth board of directors on April 10, 2025, and reviewed and approved the "Proposal on Hiring an Audit Institution for 2025". As an independent director, I believe that when serving as the company's 2024 auditor, Shun Li Chun Certified Public Accountants adhered to independent auditing standards, better fulfilled the responsibilities and obligations agreed upon by both parties, and was able to provide the company with true and fair financial and internal control audit services. I agree to hire it as the company's 2025 auditor.
(3) Supervise and inspect corporate governance and operation management
I communicate with relevant personnel of the company to gain an in-depth understanding of the company's production and operation, the improvement and implementation of internal control and other systems, the implementation of board resolutions, financial management and business development and other related matters; I pay attention to the company's daily operating conditions and governance. For each proposal reviewed by the board of directors, I first carefully review the proposed proposal materials and relevant introductions, and exercise voting rights independently, objectively and prudently on the basis of a full understanding.
4/5
4. Overall evaluation and suggestions
In 2025, as an independent director of the company, I will strictly abide by the "Company Law", "Securities Law", "Measures for the Administration of Independent Directors of Listed Companies" and other relevant regulations, and in line with the principles of objectivity, fairness and independence, I will perform my duties with integrity and diligence, take the initiative to deeply understand the company's operations and operations, and carefully review Various meeting proposals submitted by the company were carefully studied and reviewed, and the voting rights were exercised in a prudent and responsible manner; guiding suggestions were put forward in terms of corporate governance and major operating decisions, ensuring the company's standardized operation and healthy development, and safeguarding the legitimate rights and interests of the company and all shareholders.
Finally, I would like to sincerely thank the company’s senior management and relevant staff for their active cooperation and full support for my work in 2025. In order to facilitate communication with investors, my contact information is hereby announced:
(Email: [email protected])
Signature of the independent director of Innovative Medical Management Co., Ltd.: Yao Hangping April 23, 2026
5/5